This excerpt taken from the THLD 8-K filed Nov 9, 2009.
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding TH-302s uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Thresholds ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading Risk Factors in Thresholds Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on November 5, 2009 and is available from the SECs website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading Investors. Threshold does not intend to update any forward-looking statement made in this news release.
1300 Seaport Boulevard, Suite 500, Redwood City, CA 94063 tel: 650.474.8200 fax: 650.474.2529